Asieris(SH:688176)2024-01-25 10:31Group 1: Clinical Trials and Progress - APL-1202 is currently conducting three key clinical trials, with the phase I/II trial for muscle-invasive bladder cancer (MIBC) completed in September 2023, showing positive interim results to be disclosed at the 2024 ASCO-GU conference [3] - The treatment regimen for APL-1202 in the pivotal trial for high-risk NMIBC involves a 3-month administration followed by a 3-month break, continuing for 2 years, with chemotherapy maintenance for 1 year [4] - APL-1702 has achieved its primary endpoint in the international phase III trial for high-grade squamous intraepithelial lesions (HSIL) and results will be presented at the 2024 EUROGIN conference [4] Group 2: Market Potential - The global incidence of bladder cancer patients is projected to increase from 520,000 in 2016 to 736,000 by 2030, while in China, the number is expected to rise from 77,000 in 2016 to 118,000 by 2030 [4] - The number of HSIL patients in China reached 2 million in 2020 and is expected to grow to 2.1 million by 2025, indicating a significant market for APL-1702 [5] - The company plans to actively promote APL-1702 post-launch, considering factors such as traditional treatment costs and patient affordability for pricing strategies [5] Group 3: Regulatory and Disclosure Obligations - The company will communicate with regulatory authorities regarding the NDA submission for APL-1702 and will adhere to relevant disclosure obligations as per the Shanghai Stock Exchange regulations [5] - The company commits to timely information disclosure regarding clinical trial results and NDA status in compliance with regulations [5]